Retatrutide (Triple Agonist)

Retatrutide (triple agonist: GLP-1 + GIP + glucagon) adds glucagon receptor agonism to tirzepatide's dual agonism (GLP-1 + GIP). The glucagon receptor component adds thermogenesis—glucagon directly activates brown adipose tissue to increase energy expenditure—that is absent from tirzepatide. Phase 2 data: retatrutide achieved 24.2% weight loss at 48 weeks vs tirzepatide's 22.5% at 72 weeks in different trials (not a direct comparison). Retatrutide's 48-week weight loss curves were still declining, suggesting the 24.2% figure underestimates its maximum effect. Retatrutide is in Phase 3 trials and has not yet been approved.

This is the central pharmacological paradox of triple agonists. Glucagon normally signals hepatic glucose production and raises blood sugar. However, in clinical trials retatrutide produces robust glucose lowering despite glucagon receptor activation. The GLP-1 receptor activation suppresses glucagon secretion and directly enhances glucose-dependent insulin release; GIP receptor activation also enhances insulin secretion. These combined insulinotropic effects dramatically outweigh the hepatic glucagon effect at the doses used. The clinical result is net HbA1c reduction of ~2% in T2D patients—despite the glucagon agonism.

Retatrutide completed Phase 2 trials in 2023 demonstrating record weight loss (24.2% at 48 weeks in obesity; 16.9% weight loss + 2.02% HbA1c reduction in T2D). Phase 3 trials are underway (TRIUMPH program) evaluating retatrutide for obesity and T2D. FDA approval is not expected before 2026–2027. The primary competitive concern is whether its modest incremental weight loss advantage over tirzepatide (the current standard) justifies its differentiated side effect profile, particularly if glucagon agonism increases bone turnover, hepatic glucose production at higher doses, or cardiovascular risk.

Retatrutide reduces liver fat by over 80% in NAFLD patients—exceeding the hepatic fat reduction seen with semaglutide (~50–60%) or tirzepatide (~65–75%) in comparable Phase 2 populations. The glucagon receptor component is key: glucagon directly stimulates hepatic fatty acid oxidation and promotes fat mobilization from the liver. GLP-1 reduces fat uptake and de novo lipogenesis. The combined mechanisms create a particularly potent anti-steatotic effect. MASH (metabolic dysfunction-associated steatohepatitis) is an enormous unmet need, and retatrutide's hepatic efficacy makes it a leading candidate for potential MASH approval alongside or following obesity approval.

Based on Phase 2 data, retatrutide Phase 3 trials use a multi-step titration: starting at 2 mg SC weekly for 4 weeks, then escalating to 4 mg, 8 mg, and 12 mg at 4-week intervals. This slower titration vs. tirzepatide is partly driven by the glucagon receptor component, which may cause greater GI effects at higher doses. The highest dose studied in Phase 2 was 12 mg weekly, which produced the maximum weight loss outcomes. Whether a 12 mg maintenance dose will be the approved dose, or whether a higher ceiling will be tested in Phase 3, depends on tolerability data at the 12 mg level across larger populations.

Glucagon receptors are expressed on osteoblasts and osteoclasts. Glucagon signaling stimulates bone formation markers (osteocalcin, bone-specific alkaline phosphatase) in some models. However, the weight loss itself—particularly loss of mechanical loading on the skeleton from reduced adipose tissue mass—can reduce bone mineral density. Long-term data on bone outcomes in triple agonist trials is limited. Phase 3 programs for retatrutide will need to characterize any net bone effects, particularly in postmenopausal women who are already at elevated fracture risk. This remains an open safety question awaiting longer-term data.

Several triple agonist programs exist in parallel with retatrutide (Eli Lilly): pemvidutide (Altimmune) as a GLP-1/glucagon dual agonist with liver emphasis; efinopegdutide (MSD) as GLP-1/glucagon dual; CT-388 (Structure Therapeutics) as an oral GLP-1/GIP; HM15275 (Hanmi Pharmaceutical) as GLP-1/GIP/glucagon. Retatrutide is distinguished by Eli Lilly's manufacturing scale, clinical trial infrastructure, Phase 2 efficacy data quality, and integration into the company's GLP-1 agonist ecosystem (Mounjaro, Zepbound). Its head-to-head competition will ultimately be with tirzepatide—the question being whether the incremental efficacy justifies additional development risk and a higher side effect burden.

As of 2026, no completed cardiovascular outcomes trial (CVOT) data exists for retatrutide—Phase 2 data provides cardiometabolic markers (blood pressure, lipids, weight) but not hard CV event outcomes. A CVOT is expected as part of the Phase 3 program given FDA requirements for obesity drugs to demonstrate CV safety. The glucagon receptor component introduces some theoretical uncertainty: glucagon increases heart rate and hepatic glucose output, which historically raised CV safety questions. However, Phase 2 data showed no adverse cardiac signals and the GLP-1 component's established cardioprotective properties (reduced MACE, per semaglutide and liraglutide data) are expected to offset glucagon-related concerns.